Weight loss before transplant listing

Clinical stem

A 49-year-old on the path to kidney transplant is above the center’s BMI ceiling (for example, 40) and asks how to become listable.

The trap

Treating BMI as a fixed gate — either excluding the patient outright or driving rapid weight loss that sacrifices muscle, which undermines both candidacy and post-operative recovery.

Diagnostic reasoning

BMI is an imperfect surrogate in end-stage kidney disease (distorted by fluid and muscle). Pathways to candidacy include structured weight loss that preserves lean mass; metabolic/bariatric surgery (sleeve preferred, avoiding the enteric hyperoxaluria of Roux-en-Y), which is associated with higher rates of waitlisting and transplantation; and GLP-1 therapy as a pharmacologic bridge (not renally cleared).

Safety pearl

Monitor lean mass during weight loss; hold the weekly GLP-1 before anesthesia (delayed gastric emptying raises aspiration risk); after transplant, anticipate GLP-1–tacrolimus interactions — pooled data show stable levels, but monitor during titration.

What not to overclaim

Hard-outcome evidence that GLP-1–enabled listing improves post-transplant results is not yet available; the rationale is access- and physiology-based. Center BMI policies vary, so coordinate with the specific program.